Benjamin F. Edwards & Company, Inc. Sarepta Therapeutics, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.51 Billion
- Q1 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 76 shares of SRPT stock, worth $11,512. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76
Previous 3
2433.33%
Holding current value
$11,512
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding SRPT
# of Institutions
471Shares Held
79.3MCall Options Held
4.23MPut Options Held
1.21M-
Vanguard Group Inc Valley Forge, PA8.8MShares$1.33 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY5.96MShares$903 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X04.89MShares$741 Million0.36% of portfolio
-
Capital International Investors Los Angeles, CA4.82MShares$730 Million0.13% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.34MShares$658 Million6.78% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $13.3B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...